Research programme: apolipoprotein E therapies - Gladstone Institutes/Merck
Latest Information Update: 23 Mar 2010
At a glance
- Originator The J. David Gladstone Institutes
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 06 Nov 2006 Preclinical trials in Alzheimer's disease in USA (unspecified route)